Procept BioRobotics Corp.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 25 February 2026: press release. Guidance figures: 1 lowered, 8 new. The quarter’s numbers.

Key takeaways

Quarterly revenue up 12%: The company reported fourth-quarter total revenue of $76.4 million, up 12% from $68.2 million a year earlier. Third-quarter revenue was $83.3 million. Source
Procedures reached quarterly high: U.S. procedures were approximately 12,200 in the quarter, up about 69%, the highest volume the company reported. Full-year procedures were 43.3 thousand against 27.7 thousand. Source
Quarterly gross margin fell to 61%: Fourth-quarter gross margin was 61% against 64%. Management attributed the decline to lower-than-expected U.S. consumable revenue and a one-time cost of a voluntary field action. Source
Quarterly operating expenses rose: Fourth-quarter operating expenses were $77.4 million against $63.4 million, reflecting commercial expansion, BPH platform innovation and Water IV Prostate Cancer trial funding. Source
Handpiece sales to track procedures: Handpiece units had historically exceeded procedure volumes by about 8% to 16%. Management now expects the two to be closely aligned, which reduced projected 2026 handpiece revenue. Source
Field inventory cut, incentives ended: Management reduced field inventory and ended end-of-quarter purchasing incentives, which it said led to a fourth-quarter revenue shortfall. Source
Commercial organization realigned: Management said it realigned the commercial organization, set up a dedicated launch team to reduce activation variability, and adopted a more disciplined handpiece pricing strategy. Source

“At the same time, we took meaningful steps to position the Company for its next phase of growth.”
Larry Wood, Chief Executive Officer

Guidance

Area	Period	Figure	Against last quarter
Revenue Source	full year 2026	$390 million to $410 million	Lowered from $410 to $430 million
U.S. procedure growth Source	full year 2026	39% to 48%	New
Gross margin Source	full year 2026	approximately 65%	New
Operating expenses Source	full year 2026	approximately $350 million	New
Adjusted EBITDA loss Source	full year 2026	$30 million to $17 million	New
Net loss Source	full year 2026	$(91,500) to $(78,500) thousand	New
Total procedures Source	first quarter of 2026	12,000 to 12,800	New
Total revenue Source	first quarter of 2026	$79 million to $82 million	New
Handpiece price Source	full year 2026	$3,500 per unit	New

What changed from last quarter

Guidance lowered: Full-year 2026 revenue guidance lowered from $410 to $430 million to $390 million to $410 million. Source
New guidance: Full-year 2026 U.S. procedure growth guidance of 39% to 48% given for the first time in these documents. Source
New guidance: Full-year 2026 gross margin, operating expense and adjusted EBITDA loss guidance given; the prior release gave revenue only. Source
New guidance: First-quarter 2026 procedure and revenue guidance given. Source
New: Handpiece unit sales and procedure volumes to be forecast in close alignment. Source
New: Commercial organization realigned, a dedicated launch team set up, and a handpiece pricing strategy adopted. Source
Ended: End-of-quarter purchasing incentives eliminated, and field inventory levels reduced. Source

Results and growth drivers

Quarterly revenue up 12%: The company reported fourth-quarter total revenue of $76.4 million, up 12% from $68.2 million a year earlier. Third-quarter revenue was $83.3 million. Source
Full-year revenue up 37%: Full-year 2025 revenue was $308.1 million, up 37%, driven by U.S. system placements and more handpieces sold. Source
Quarterly net loss widened: Fourth-quarter net loss was $29.8 million against $18.9 million a year earlier. Full-year net loss was $95.6 million against $91.4 million. Source
Loss per share narrowed for year: Net loss per share, basic and diluted, was $(0.53) for the quarter against $(0.35), and $(1.72) for the full year against $(1.75). Source
Adjusted EBITDA loss by period: Adjusted EBITDA loss was $19.0 million in the quarter against $10.3 million. The full-year loss was $50.2 million against $61.1 million. Source

Segments and regions

U.S. revenue up 10%: U.S. revenue was $66.6 million, up 10% from $60.4 million, primarily from higher handpiece revenue. Source
U.S. systems flat, consumables up: U.S. system revenue was $27.6 million, flat year over year. U.S. handpiece and consumable revenue rose 16% to $34.0 million. Source
International revenue up 25%: International revenue was $9.8 million, up 25% from $7.8 million. Full-year international revenue was $37.7 million against $24.0 million. Source
U.S. service revenue rose: U.S. service revenue was $5.0 million against $3.4 million a year earlier. Full-year U.S. service revenue was $17.7 million. Source

“We believe these actions are essential to our long-term goals of sustained high growth and establishing a favorable financial profile.”
Larry Wood, Chief Executive Officer

Installed base and procedures

Procedures reached quarterly high: U.S. procedures were approximately 12,200 in the quarter, up about 69%, the highest volume the company reported. Full-year procedures were 43.3 thousand against 27.7 thousand. Source
Handpieces sold up 7%: U.S. handpieces sold were approximately 9,400 in the quarter, up about 7% from the prior year period. Source
Handpiece price rose 5%: Handpiece average selling price rose 5% from the third quarter to $3,340. Source
U.S. install base reached 718: The U.S. install base was 718 systems at year-end, up 42% year over year, from 653 at September 30. Source
Systems placed rose for year: Fourth-quarter U.S. systems placed were 65, against 60 a year earlier. Full-year placements were 213 against 190. Source

Costs, margins and pricing

Quarterly gross margin fell to 61%: Fourth-quarter gross margin was 61% against 64%. Management attributed the decline to lower-than-expected U.S. consumable revenue and a one-time cost of a voluntary field action. Source
Full-year gross margin rose to 64%: Full-year gross margin was 64% against 61%, attributed to overhead absorption and U.S. handpiece mix. Source
Quarterly operating expenses rose: Fourth-quarter operating expenses were $77.4 million against $63.4 million, reflecting commercial expansion, BPH platform innovation and Water IV Prostate Cancer trial funding. Source
Full-year operating expenses up 28%: Full-year operating expenses were $300.1 million against $233.7 million, with added sales and marketing spend to expand the commercial organization a main driver. Source

“Furthermore, we successfully reduced field inventory levels and eliminated end-of-quarter purchasing incentives, which led to a fourth quarter revenue shortfall but improved handpiece average selling price by approximately 5%.”
Larry Wood, Chief Executive Officer

Demand and order book

Handpiece sales to track procedures: Handpiece units had historically exceeded procedure volumes by about 8% to 16%. Management now expects the two to be closely aligned, which reduced projected 2026 handpiece revenue. Source
Field inventory cut, incentives ended: Management reduced field inventory and ended end-of-quarter purchasing incentives, which it said led to a fourth-quarter revenue shortfall. Source
Deferred revenue increased: Deferred revenue was $13.0 million at December 31, 2025, against $10.7 million at September 30 and $9.6 million a year earlier. Source

Capital, cash and balance sheet

Cash position at $289.5 million: Cash, cash equivalents and restricted cash were $289.5 million at December 31, 2025, against $297.3 million at September 30. Source
Inventory higher than prior year: Balance sheet inventory was $70.7 million at December 31, 2025, against $56.2 million a year earlier and $66.7 million at September 30. Source
Long-term debt and receivables steady: Long-term debt was $51.6 million, against $51.5 million a year earlier. Accounts receivable, net was $83.5 million, unchanged from a year earlier. Source

Strategy, forecasting and leadership

Commercial organization realigned: Management said it realigned the commercial organization, set up a dedicated launch team to reduce activation variability, and adopted a more disciplined handpiece pricing strategy. Source
Forecasting approach changed for 2026: Management said its decision to forecast procedure and handpiece volumes closely together reduced the projected 2026 handpiece revenue guidance. Source
Sales force realignment disrupts near term: Management said short-term disruption from the sales force realignment was one factor behind the 2026 guidance reset. Source

Coming up, as management said on 25 February 2026

Investor Day in New York: The company will host an in-person investor day on February 26, 2026 at Nasdaq headquarters in New York, starting 8:00am Eastern, with a webcast and archived recording. Source

Figures management reported

Figure	Reported
U.S. procedures (Q4) Source	approximately 12,200
U.S. handpieces sold (Q4) Source	approximately 9,400
U.S. install base (year end) Source	718 systems
U.S. systems placed (Q4) Source	65
Handpiece average selling price (Q4) Source	$3,340

Risks management discussed

Operational: Management cited short-term disruption from the sales force realignment as a factor in the 2026 guidance reset. Source
Demand: Fourth-quarter gross margin was affected by lower-than-expected U.S. consumable revenue. Source
Regulatory: A one-time cost tied to a voluntary field action also reduced fourth-quarter gross margin. Source
Operational: Management set up a dedicated launch team to reduce variability in customer system activation. Source

Earlier plans management reported on

Not stated: Management reset the 2026 revenue range from the earlier $410 to $430 million figure to $390 to $410 million. Source
Not stated: Management said it expects handpiece unit sales and procedure volumes to be closely aligned going forward. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.

As filed with the SEC

Open the filing on EDGAR

PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

SAN JOSE, Calif., February 25, 2026 -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025.

“In the fourth quarter, we delivered our highest procedure volume to date - approximately 12,200 - and sold 65 new systems, marking our strongest capital quarter,” said Larry Wood, Chief Executive Officer. “At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commercial organization, established a dedicated launch team to reduce activation variability, and implemented a more disciplined handpiece pricing strategy. Furthermore, we successfully reduced field inventory levels and eliminated end-of-quarter purchasing incentives, which led to a fourth quarter revenue shortfall but improved handpiece average selling price by approximately 5%.”

Fourth Quarter 2025 Financial Results

Total revenue of $76.4 million for the fourth quarter of 2025, an increase of 12% compared to the prior year period in 2024
U.S. procedures of approximately 12,200 for the fourth quarter of 2025, an increase of approximately 69% compared to the prior year period
U.S. handpieces sold of approximately 9,400 for the fourth quarter of 2025, an increase of approximately 7% compared to the prior year period
Fourth quarter of 2025 handpiece average selling price increased 5% sequentially to $3,340
2025 ending U.S. install base of 718 systems, representing a 42% increase compared to the prior year period
International revenue of $9.8 million for the fourth quarter of 2025, an increase of 25% compared to the prior year period in 2024

Total revenue for the fourth quarter of 2025 was $76.4 million, an increase of 12% compared to the prior year period. U.S. revenue was $66.6 million, representing growth of 10% compared to the prior year period. The increase was primarily driven by increased handpiece revenue. U.S. handpiece and consumable revenue for the fourth quarter of 2025 was $34.0 million, an increase of 16% compared to the prior year period. U.S. system revenue for the fourth quarter of 2025 was $27.6 million, which was flat compared to the prior year period. As of December 31, 2025, the install base of robotic systems in the U.S. was 718 systems, an increase of 42% compared to the prior year period. International revenue was $9.8 million for the quarter, an increase of 25% compared to the prior year period.

Gross margin for the fourth quarter 2025 was 61% compared to 64% in the prior year period. Gross margin decline in the fourth quarter was primarily driven by lower-than-expected U.S. consumable revenue, as well as a one-time cost associated with a voluntary field action.

Operating expenses in the fourth quarter of 2025 were $77.4 million, compared with $63.4 million in the prior year period. The increase in operating expenses reflects continued investment to support commercial expansion, innovation across our BPH platform technology and increased funding for our Water IV Prostate Cancer trial.

Net loss was $29.8 million for the fourth quarter of 2025, compared to a loss of $18.9 million in the prior year period. Adjusted EBITDA* was a loss of $19.0 million for the fourth quarter of 2025, compared to a loss of $10.3 million in the prior year period.

Cash, cash equivalents and restricted cash balances as of December 31, 2025, totaled $289.5 million.

Full Year 2025 Financial Results

Revenue for the full year 2025 was $308.1 million, an increase of 37% compared to the prior year period. The growth was primarily driven by increases in U.S. revenue attributable to system placements and increased handpieces sold.

Gross margin for full year 2025 was 64%, compared to 61% for the full year 2024. Gross margin improvement was primarily due to improved overhead absorption and favorable revenue mix of U.S. handpieces sold.

Operating expenses were $300.1 million for the full year 2025, compared to $233.7 million for the full year 2024, an increase of 28%. The increase was driven by increased sales and marketing expenses primarily to expand the commercial organization, and increased research and development and general and administrative expenses.

Net loss was $95.6 million for the full year 2025, compared to $91.4 million for the full year 2024. Adjusted EBITDA was a loss of $50.2 million for full year 2024, compared to a loss of $61.1 million for the full year 2024.

Full Year 2026 Financial Guidance

“Historically, handpiece unit sales exceeded procedure volumes by approximately 8% to 16%. Going forward, we expect handpiece unit sales and procedure volumes to be closely aligned,” said Larry Wood. “While annual U.S. procedure growth will be in the range of 39% to 48%, our decision to forecast procedure and handpiece volumes in close alignment has reduced our projected 2026 handpiece revenue guidance; however, this impact is meaningfully offset by higher handpiece prices of $3,500 per unit. Considering these factors, together with the short-term disruption associated with the sales force realignment, we are resetting our 2026 guidance to $390 to $410 million, representing annual growth of 27% to 33%. We believe these actions are essential to our long-term goals of sustained high growth and establishing a favorable financial profile.”

The Company expects revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period
The Company expects full year 2026 U.S. procedure growth to be in the range of 39% to 48% compared to the prior year period
The Company expects full year 2026 gross margin to be approximately 65%
The Company expects full year 2026 operating expenses to be approximately $350 million
The Company expects full year 2026 adjusted EBITDA* loss to be in the range of $30 million to $17 million

First Quarter 2026 Financial Guidance

The Company expects total procedures for the first quarter of 2026 to be in the range of 12,000 to 12,800, which represents growth of 31% to 36% compared to the prior year period.
Total revenue for the first quarter of 2026 is expected to be in the range of $79 million to $82 million dollars, which represents growth of 14% to 19% to the prior year period.

*Adjusted EBITDA is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).

Webcast and Conference Call Information

PROCEPT BioRobotics will host a conference call to discuss the fourth quarter 2025 financial results on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the links below:

Webcast link for interested listeners:
https://edge.media-server.com/mmc/p/mej8z6sd/
Dial-in registration for sell-side research analysts:
https://register-conf.media-server.com/register/BIf439042f85a64a1f98d8f534e4d10fcb

Investor Day in New York and Webcast

The Company will also host an in-person investor day event on Thursday, February 26, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time. A live, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation® therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Use of Non-GAAP Financial Measures (Unaudited)

This press release references Adjusted EBITDA, a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company defines Adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization and stock-based compensation. Non-GAAP financial measures are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to any other performance measures derived in accordance with GAAP.

The Company believes that presenting Adjusted EBITDA provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.

Forward Looking Statements

Forward-looking statements notice

This release contains forward‐looking statements within the meaning of federal securities laws, including with respect to the Company’s projected financial performance for full year 2026, statements regarding the potential utilities, values, benefits and advantages of Aquablation therapy performed using PROCEPT BioRobotics’ products, including AquaBeam or Hydros Robotic Systems, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on the Company’s current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which the Company is not currently aware. Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, procedure growth, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margins, profitability, operating expenses, installed base growth, commercial momentum and overall business strategy. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s annual report on Form 10-K filed with the SEC on February 27, 2025, and amended on April 11, 2025, and subsequent quarterly reports on Form 10-Q. PROCEPT BioRobotics does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press release.

Important Safety Information

All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/

PROCEPT BioRobotics Corporation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except per share data)

	Three Months Ended December 31,		Twelve Months Ended December 31,
	2025	2024	2025	2024
Revenue	$76,383	$68,236	$308,054	$224,498
Cost of sales	30,070	24,564	111,828	87,399
Gross profit	46,313	43,672	196,226	137,099
Operating expenses:
Research and development	19,056	15,066	71,277	62,298
Selling, general and administrative	58,298	48,316	228,808	171,415
Total operating expenses	77,354	63,382	300,085	233,713
Loss from operations	(31,041)	(19,710)	(103,859)	(96,614)
Interest expense	(894)	(969)	(3,586)	(4,184)
Interest and other income, net	2,280	2,191	12,063	9,753
Loss before income taxes	(29,655)	(18,488)	(95,382)	(91,045)
Provision for income taxes	190	368	190	368
Net loss	$(29,845)	$(18,856)	$(95,572)	$(91,413)
Net loss per share, basic and diluted	$(0.53)	$(0.35)	$(1.72)	$(1.75)
Weighted-average common shares used to
Compute net loss per share attributable to
Common shareholders, basic and diluted	56,071	55,838	55,544	52,125

PROCEPT BioRobotics Corporation

RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

(Unaudited, in thousands)

	Three Months Ended December 31,		Twelve Months Ended December 31,
	2025	2024	2025	2024
Net loss	$(29,845)	$(18,856)	$(95,572)	$(91,413)
Depreciation and amortization expense	1,709	1,453	6,390	5,234
Stock-based compensation expense	10,842	9,085	47,603	31,840
Interest (income) and interest expense, net	(1,719)	(2,017)	(8,632)	(6,711)
Adjusted EBITDA	$(19,013)	$(10,335)	$(50,211)	$(61,050)

PROCEPT BioRobotics Corporation

RECONCILIATION OF GAAP NET LOSS TO ADJUSTED 2026 EBITDA Guidance

(Unaudited, in thousands)

	For the Year Ending December 31, 2026
	LOW	HIGH
Net loss	$(91,500)	$(78,500)
Depreciation and amortization expense	7,500	7,500
Stock-based compensation expense	59,000	59,000
Interest (income) and interest expense, net	(5,000)	(5,000)
Adjusted EBITDA	$(30,000)	$(17,000)

PROCEPT BioRobotics Corporation

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands)

	December 31, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$286,503	$333,725
Accounts receivable, net	83,533	83,496
Inventory	70,694	56,168
Prepaid expenses and other current assets	9,648	8,453
Total current assets	450,378	481,842
Restricted cash, non-current	3,038	3,038
Property and equipment, net	30,399	26,709
Operating lease right-of-use assets, net	17,538	18,941
Intangible assets, net	709	932
Other assets	6,019	2,555
Total assets	$508,081	$534,017
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$17,285	$10,032
Accrued compensation	23,175	21,537
Deferred revenue	13,048	9,565
Operating leases, current	2,214	1,910
Loan facility liability	-	2,000
Other current liabilities	10,073	8,089
Total current liabilities	65,795	53,133
Long-term debt	51,615	51,472
Operating leases, non-current	24,654	26,868
Other liabilities	147	324
Total liabilities	142,211	131,797
Stockholders’ equity:
Additional paid-in capital	1,007,390	948,091
Accumulated other comprehensive gain	37	114
Accumulated deficit	(641,557)	(545,985)
Total stockholders’ equity	365,870	402,220
Total liabilities and stockholders’ equity	$508,081	$534,017

PROCEPT BioRobotics Corporation

REVENUE BY TYPE AND GEOGRAPHY

(Unaudited, in thousands)

	Three Months Ended December 31,		Twelve Months Ended December 31,
	2025	2024	2025	2024
U.S.
System sales and rentals	$27,600	$27,636	$93,000	$78,614
Handpieces and other consumables	34,001	29,325	159,669	110,542
Service	4,986	3,428	17,709	11,316
Total U.S. revenue	66,587	60,389	270,378	200,472
Outside of U.S.
System sales and rentals	2,953	3,711	13,132	11,685
Handpieces and other consumables	5,977	3,684	21,777	10,914
Service	866	452	2,767	1,427
Total outside of U.S. revenue	9,796	7,847	37,676	24,026
Total revenue	$76,383	$68,236	$308,054	$224,498

PROCEPT BioRobotics Corporation

QUARTERLY U.S. INSTALL BASE AND PROCEDURES

(Unaudited, in thousands)

	Q1'23	Q2'23		Q3'23		Q4'23		Q1'24		Q2'24		Q3'24		Q4'24		Q1'25		Q2'25		Q3'25		Q4'25		FY 23		FY 24		FY 25
U.S. Install Base
Beginning install base	167		192		233		271		315		354		400		445		505		547		595		653		167		315		505
Systems placed	25	41		38		44		39		46		45		60		42		48		58		65		148		190		213
Ending install base	192	233		271		315		354		400		445		505		547		595		653		718		315		505		718
U.S Procedures (000)	3.0	3.6		4.3		5.6		6.1		7.0		7.4		7.2		9.3		10.8		11.0		12.2		16.5		27.7		43.3

Contacts
Matt Bacso
VP, Investor Relations and Business Operations m.bacso@procept-biorobotics.com